BIOMAT Database Logo BIOMAT Database Logo

Successful ceftazidime-avibactam therapy in a patient with multidrug-resistant Pseudomonas aeruginosa infective endocarditis. 2022

Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Infectious Diseases Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Pontevedra, Spain. olalla.lima@gmail.com.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004696 Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening. Infective Endocarditis,Endocarditides,Endocarditides, Infective,Endocarditis, Infective,Infective Endocarditides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug

Related Publications

Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
July 2019, The Journal of infectious diseases,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Successful therapy of Pseudomonas aeruginosa endocarditis with ceftazidime and tobramycin.
August 1987, The American journal of medicine,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
March 2020, Acta microbiologica et immunologica Hungarica,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Ceftolozane-tazobactam- and ceftazidime-avibactam-resistant Pseudomonas aeruginosa mastoiditis.
January 2020, Access microbiology,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam.
May 2021, Scientific reports,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa.
August 2019, Journal of paediatrics and child health,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Ceftazidime-avibactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Central Nervous System Infection in Pediatric Patient: A Case Report.
May 2022, The Pediatric infectious disease journal,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.
December 2018, Journal of global antimicrobial resistance,
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa.
May 2021, Infectious diseases (London, England),
Olalla Lima, and Adrián Sousa, and Antón Filgueira, and Antón Otero, and Andrea Cabaleiro, and Lucía Martinez-Lamas, and Francisco Vasallo, and M Teresa Pérez-Rodríguez
A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate.
March 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Copied contents to your clipboard!